Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BIRC5 expression
i
Other names:
BIRC5, API4, EPR-1, survivin, Baculoviral IAP repeat containing 5
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
332
Related biomarkers:
Expression
Mutation
‹
BIRC5 overexpression (2)
BIRC5 overexpression (2)
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
DPX-Survivac and Checkpoint Inhibitor in DLBCL (SPiReL) (NCT03349450)
Phase 2
Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Completed
Phase 2
Sunnybrook Health Sciences Centre
Completed
Last update posted :
11/02/2023
Initiation :
03/13/2018
Primary completion :
10/31/2021
Completion :
07/18/2023
BIRC5
|
BIRC5 expression
|
Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S) • cyclophosphamide intravenous
Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery (NCT06015269)
Phase 1
Shanghai Cell Therapy Group Co.,Ltd
Shanghai Cell Therapy Group Co.,Ltd
Recruiting
Phase 1
Shanghai Cell Therapy Group Co.,Ltd
Recruiting
Last update posted :
08/29/2023
Initiation :
08/01/2023
Primary completion :
07/01/2025
Completion :
07/01/2025
TP53
|
TP53 expression • BIRC5 expression
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) (NCT02851056)
Phase 1
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Resear...
Completed
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Completed
Last update posted :
11/11/2022
Initiation :
09/27/2016
Primary completion :
07/16/2018
Completion :
08/09/2018
BIRC5
|
BIRC5 expression
Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma (NCT04873180)
Phase N/A
Sohag University
Sohag University
Completed
Phase N/A
Sohag University
Completed
Last update posted :
05/07/2021
Initiation :
01/01/2020
Primary completion :
06/30/2020
Completion :
12/30/2020
BIRC5
|
BIRC5 expression • BIRC5 overexpression
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (NCT02123381)
Phase 2
Sichuan Cancer Hospital and Research Institute
Sichuan Cancer Hospital and Research In...
Unknown status
Phase 2
Sichuan Cancer Hospital and Research Institute
Unknown status
Last update posted :
03/17/2020
Initiation :
04/01/2014
Primary completion :
07/01/2020
Completion :
07/01/2020
TP53 • BIRC5
|
TP53 expression • BIRC5 expression
|
Erbitux (cetuximab)
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00620321)
Phase 2
Eli Lilly and Company
Eli Lilly and Company
Completed
Phase 2
Eli Lilly and Company
Completed
Last update posted :
09/09/2019
Initiation :
03/01/2008
Primary completion :
01/01/2010
Completion :
01/01/2010
BIRC5
|
BIRC5 expression
|
cytarabine • idarubicin hydrochloride • gataparsen (LY2181308)
Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients (NCT00129376)
Phase 2
Spanish Breast Cancer Research Group
Spanish Breast Cancer Research Group
Completed
Phase 2
Spanish Breast Cancer Research Group
Completed
Last update posted :
07/05/2019
Initiation :
02/01/2003
Primary completion :
07/01/2005
Completion :
02/01/2010
BIRC5
|
BIRC5 expression • BIRC5 overexpression • CDKN1B expression • TOP2A expression
|
docetaxel • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma (NCT01764477)
Phase 1
Prism Pharma Co., Ltd.
Prism Pharma Co., Ltd.
Completed
Phase 1
Prism Pharma Co., Ltd.
Completed
Last update posted :
08/17/2017
Initiation :
04/01/2013
Primary completion :
10/01/2015
Completion :
10/01/2015
BIRC5 • MMP7
|
BIRC5 expression
|
gemcitabine • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • foscenvivint (PRI724)
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer (PRIMIER) (NCT02413853)
Phase 2
University of Southern California
University of Southern California
Withdrawn
Phase 2
University of Southern California
Withdrawn
Last update posted :
04/17/2017
Initiation :
11/01/2015
Primary completion :
11/01/2017
Completion :
11/01/2018
BRAF • BIRC5
|
BIRC5 expression
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • foscenvivint (PRI724)
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (NCT01250470)
Phase 1
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Completed
Phase 1
Roswell Park Cancer Institute
Completed
Last update posted :
02/27/2017
Initiation :
09/05/2012
Primary completion :
05/29/2014
Completion :
05/29/2014
IFNG
|
BIRC5 expression
|
SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy (NCT00990587)
Phase 1
University Health Network, Toronto
University Health Network, Toronto
Completed
Phase 1
University Health Network, Toronto
Completed
Last update posted :
06/22/2015
Initiation :
10/01/2009
Primary completion :
05/01/2013
BIRC5
|
BIRC5 expression
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login